ABSTRACT Background: Crohn disease (CD) and ulcerative colitis (UC) are 2 common inflammatory bowel diseases (IBDs) associated with intestinal inflammation and tissue damage. Oxidative stress is suggested to play a major role in the initiation and progression of IBD. Vitamin C (ascorbate, ascorbic acid) supplementation has reduced oxidative stress in persons with IBD. The role of ascorbate transporters in IBD remains to be determined. SLC23A1 is a major ascorbate transporter in the intestinal tract, and some of its genetic variants have been associated with severely decreased ascorbate transport and lower systemic concentrations. Objective: This study aimed to determine whether common genetic variants in the vitamin C transporter SLC23A1 are associated with the risk of IBD. Design: Genomic DNA samples from patients with CD (n = 162) and UC (n = 149) from the Manitoba IBD Cohort Study and ethnically matched controls (n = 142) were genotyped for 3 SLC23A1 polymorphisms (rs6596473, rs33972313, and rs10063949) by using TaqMan assays. Results: Variation at rs10063949 (G allele for heterozygote and homozygote) was associated with increased susceptibility to CD (OR: 2.54; 95% CI: 1.38, 4.66; OR: 4.72; 95% CI: 2.53, 8.81; P , 0.0001; respectively). A strong linkage disequilibrium (LD) was observed across the SLC23A1 region (variation rs6596473 with rs10063949) for CD and UC (D# = 0.94 and 0.96, respectively). The risk alleles confirmed a haplotype (CGG) that is carried more in CD patients (65.3%, P , 0.0001) than in controls (43.5%). Conclusions: A genetic variant (rs10063949-G) in the SLC23A1 ascorbate transporter locus was identified and is associated with an increased risk of CD in a white Canadian IBD cohort. The presented evidence that SLC23A1 variations can modulate the risk of CD has implications for understanding ascorbate transport in CD patients and provides a novel opportunity toward individualized nutritional therapy for patients carrying the disease-associated genotype.
INTRODUCTION
Inflammatory bowel disease (IBD) 4 includes Crohn disease (CD) and ulcerative colitis (UC), and results from the interface of environmental factors with an aberrant immune response in genetically susceptible individuals. IBD is accompanied by excessive production of reactive oxygen species, which play an important role in the pathogenesis of the disease through oxidative tissue damage (1) . The antioxidant defense system of the intestinal mucosa is impaired in IBD patients, which results in increased oxidative injury and eventually delayed recovery of the inflamed mucosa (2, 3) . Intestinal biopsies from IBD patients have shown deficiencies and imbalances in the levels of different antioxidants, including vitamin C (ascorbate) in inflamed mucosa compared with normal mucosa (2, 4) .
Ascorbate is the primary essential water-soluble antioxidant from the diet, which acts as a direct scavenger of reactive oxygen species and contributes to prevention of oxidative damage. Ascorbate is also a redox cofactor for enzymes required for the synthesis of collagen, carnitine, and neurotransmitters (5-7). The antioxidant property of ascorbate is thought to prevent chronic diseases involving inflammatory events, including atherosclerosis (8) (9) (10) , cancer (11) , and type 2 diabetes (12, 13) . In IBD patients, a loss of 35% to 73% total and reduced ascorbate has been observed in inflamed mucosa, which contributes to the overall loss of its antioxidant capacity (4) . Plasma deficiencies of ascorbate have also been observed in IBD patients (14) (15) (16) and has been attributed to extensive depletion of ascorbate as an antioxidant or to inadequate dietary uptake (17) . Whether reduction in ascorbate concentrations in inflammatory tissue in IBD is more cause or effect is unknown.
The sodium-dependent ascorbate transporter 1 (SLC23A1) is the major ascorbate transporter in the intestinal epithelium (18, 19) and is also found in cells involved in the immune defense (20, 21) . Cellular ascorbic acid uptake is enhanced when SLC23A1 is present (19, 22, 23) . Global elimination of slc23a1 in the mouse results in a dramatic decrease of ascorbic acid concentrations in cells and organs expressing slc23a1 in the wild type (19) . A nonsynonymous genetic variation has been shown to reduce the transporters capacity by w90% in vitro (19) . We hypothesized that variation in the human SLC23A1 gene down regulates transporter activity and reduces intracellular antioxidant capac-ity, resulting in impeding the enterocyte barrier function or modulating the capability of some intestinal immune cells to respond to oxidative stress. Therefore, the objective of this study was to examine whether genetic variation in the SLC23A1 gene could modulate the susceptibility to IBD and/or the severity of its complications.
SUBJECTS AND METHODS

Study design and population
The study design was previously described (24) . Briefly, clinical data were collected from case records of participants in the Manitoba IBD Cohort Study, initiated in 2002. At enrollment in the Cohort Study, participants were $18 y of age (18-80 y) with a diagnosis made within the previous 7 y (median: 4.3 y). Controls included healthy individuals with no chronic immune diseases or first-degree relatives with chronic immune diseases. A total of 311 persons with IBD (CD, n = 162; UC n = 149) and 142 healthy controls were studied. All of the study population (cases and controls) was white. The diagnosis and extent of IBD was determined based on surgical, endoscopic, radiologic, and histologic data. Phenotype was assigned according to the Montreal Classification (25) . Every subject signed an informed consent form, and this study was approved by the Biomedical Research Ethics Board at University of Manitoba.
Single nucleotide polymorphism selection and genotyping methods
Extensive sequencing analysis of the pattern of common genetic variation of SLC23A1 gene was previously performed defining haplotype tagging single nucleotide polymorphisms (SNPs) for the gene (26) . Subsequently, a haplotype-based approach was implemented, and 3 SNPs in the SLC23A1 gene were identified (rs6596473C.G, rs33972313 A.G, and rs10063949 G.A). Variants were selected because they are located in the 5#, middle, and 3# region of SLC23A1 and based on potential functional affect (eg, rs33972313 is nonsynonymous and had been shown to influence plasma ascorbic acid concentrations).
Genomic DNA was isolated from peripheral white blood cells as previously described (27) . Genotyping was performed for all subjects for 3 SNPs in SLC23A1 by using TaqMan Real-Time polymerase chain reaction assays (Applied Biosystems), the assay condition for each optimized assay are shown in Table 1 . Approximately 8% blinded quality control samples (36 individuals) were assayed 4 times, which showed 100% concordance.
Statistical analysis
Statistical analyses were performed by using SAS version 9.3 (SAS Institute Inc). All tests were 2-sided, and P , 0.05 was considered significant. Each of the 3 SNPs was analyzed individually by using allele frequencies and carriage rates for association with CD and UC. Binary logistic regression was used to estimate ORs and 95% CIs for the association between genotypes and CD and UC risk, adjusted for age and sex. Allelic frequencies and genotype frequencies were determined in UC patients, CD patients, and controls. The homozygous common genotype was considered the reference group. In alternative analyses, a dominant model of inheritance was used to compare risk in the combined group of homozygous rare and heterozygotes genotypes with risk among the common homozygous genotype. Based on phenotype, comparisons of genetic frequencies and allelic frequencies were determined between UC patients, CD patients, and controls by means of a 2 3 2 contingency table and chi-squared test statistics. Haplotypes were calculated by using Haploview 4.2 (Broad Institute). Multinomial logistic regression was used for the association between genotypes and phenotype for CD and UC patients.
RESULTS
One hundred sixty-two patients with CD, 149 patients with UC, and 142 ethnically matched healthy controls (n = 142) were genotyped for 3 SLC23A1 polymorphisms. Baseline characteristics of the study population are shown in Table 2 . Genotype frequencies are summarized in Table 3 (CD) and Table 4 (UC). Genotype frequencies for all of the polymorphisms were in Hardy-Weinberg equilibrium within the CD and UC groups.
Of the 3 variants in SLC23A1 examined, the rs10063949-G allele is associated with increased CD risk ( Table 3) . Carriage of one (heterozygote) or 2 (homozygote) copies of the minor rs10063949 allele (G) was associated with an increased risk of CD (OR: 2.54; 95% CI: 1.38, 4.66; OR: 4.72; 95% CI: 2.53, 8.81, P , 0.001; respectively). None of the SNPs were associated with UC risk.
A strong linkage was observed across the SLC23A1 gene (D# = 0.94 between rs6596473 and rs10063949) in persons with CD ( Figure 1A ) and the haplotype CGG, which is carried in persons with CD (OR: 2.40; 95% CI: 1.54, 3.88; P , 0.0001) ( Table 3) .
Strong linkage (D#= 0.96) in the SLC23A1 locus was also observed in UC patients for the 2 SNPs (rs6596473 and (Table 4) . No correlation was found between the presence of any genotype and specific phenotypes for CD and UC (data not shown).
DISCUSSION
Here, for the first time, we identified a variation in the sodiumdependent ascorbic acid transporter gene SLC23A1 that is associated with CD, but not with UC. This finding confirms our hypothesis that a disturbance in the antioxidant balance could contribute to the development and severity of IBD. The rs10063949-G allele in the SLC23A1 gene is associated with an increased CD risk. Of persons with CD, two-thirds carried the G allele, corresponding to a CD risk that is elevated by 2.5 times compared with the rs10063949-A carriers. The rs10063949-GG genotype was significantly overtransmitted in the CD patients (47.5%) compared with the controls (25.4%). An allele dosage effect resembling haploinsufficiency was evident. Compared with rs10063949-AA homozygotes the 10063949-AG heterozygotes had a 2.5-fold elevated risk of CD, and the 10063949-GG homozygotes had a 4.7-fold elevated CD risk. No relation was observed between genetic variants in SLC23A1 and UC.
The SNP rs10063949 is located within the promoter region of the SLC23A1 gene, which contains a variety of regulatory elements, such as hepatocyte nuclear factor 1 (HNF1), which is required for tissue specific transcription (29) . Assuming that SNP rs10063949 contributes to intestinal inflammation, it would most likely act through differential regulation of SLC23A1 expression, which consequently would result in reduced cellular accumulation of ascorbate. In the current study, finding a genetic alteration in the SLC23A1 transporter gene in CD suggests that the observation of low ascorbate concentrations in inflamed mucosa in the study by Head and Jurenka (2) may be as much a cause of inflammation as effect.
The implication of the association between SNP rs10063949 and CD but not UC is undetermined. We suggest 3 possible celltype specific mechanisms that could by themselves, or in combination with one another, cause the differential association. If one or all of them gets validated in future biological and clinical studies, SNP rs10063949 could be used as a predictive biomarker for CD. Furthermore, it should be determined whether it could also serve as a diagnostic biomarker for dietary intervention with ascorbate. First, cell-type specific transcription factors regulating SLC23A1 expression in immune regulatory cells involved in the development of CD, but not UC, might be affected by SNP rs10063949. SLC23A1 is expressed in lymphocytes; however, the specific expression during hematopoiesis, and therefore in the different types of lymphocytes and leukocytes in general, is not defined. Future genomic and functional studies should determine SLC23A1 expression patterns in all lymphocyte types (including natural killer cells), to define if indeed ascorbate accumulates differently in carriers of the SNP 10063949 genotypes. The concentrations of ascorbate will determine the antioxidative capacity (11) and as a consequence would contribute to the differential regulation of gene expression influencing CD but not UC risk.
A second possible mechanism addresses a potential dysregulation of macrophage function through reduction in ascorbate uptake of macrophages in epithelioid granulomas. A granuloma is a collection of macrophages and other inflammatory cells. Epithelioid granulomas are among the most specific microscopic features of CD, distinguishing it from UC (30) . Intracellular ascorbic acid has a regulatory role in the granulocyte macrophage-colony-stimulating signaling response (31), which is involved in proinflammatory processes, and therefore could determine the severity of CD. A third possible explanation is related to the fact that the intestinal epithelium constitutes a physical barrier that contains immunogenic bacteria within the intestinal lumen, and elevated oxidative stress can impede this barrier function (32, 33) . SLC23A1 is highly expressed in intestinal epithelial enterocytes, where its downregulation may lead to decreased intracellular ascorbic acid concentrations to compromise the physical barrier function against immunogenic bacteria and/or the ability to withstand prolonged intrinsic macrophage challenges. This by itself may not explain the causality of a genetic variation associated with CD but not with UC; however, it could enhance the severity of any immune dysregulations specific for CD. This might be even more potentiated by the fact that oxidative stress in epithelial cells and macrophages leads to the activation of the nuclear factor k-B, an activator of prooxidative genes such as lipoxygenase, cycloxygenase-2, and inducible-nitric oxide synthase, which leads to further elevated oxidative stress and reduced function of the intestinal barrier (34, 35) .
Previously, the 3 SNPs examined in this study were shown to be associated with circulating plasma ascorbic acid; however, the results are inconsistent (5, 36, 37) . The inconsistency and/or heterogeneity among the results from different studies may be largely accounted for by the sensitivity of analyses for measuring plasma ascorbate, different assay protocols, and many confounding factors that often make the interpretation of observational data difficult (36) . Therefore, there is a need for additional studies to confirm a possible relation between SLC23A1 genetic variations and circulating plasma ascorbic acid. In the current study, because of sampling collection methods, we were not able to include measurements of plasma ascorbic acid as a biomarker for ascorbate status. Although a limitation of this study, we speculate that the association of the genetic variation to CD may not influence plasma ascorbic acid concentrations, which are determined through renal reabsorption rather than intestinal absorption (24) .
Compared with current genome-wide association studies, our Manitoban population-based case-control cohort could be considered suboptimal in terms of sample size (38) . However, a previous study of the Manitoba IBD Cohort (39) found significant associations for some of the previously described IBDassociated SNPs identified by genome-wide association studies in other large population-based cohorts. Therefore, these results from a well phenotyped cohort of moderate size are noteworthy, but nonetheless should be reproduced in other cohorts.
If, as we hypothesize, intracellular ascorbate concentrations of specific intestinal cell types will decrease by the action of SNPs in SLC23A1, a supplementation with dehydroascorbate would be worthy of study as the therapy of choice to compensate for this shortfall. Dehydroascorbate, the oxidized form of vitamin C, does not exist under physiologic conditions (40, 41) . However, if supplemented externally, dehydroascorbate enters the cell through facilitated glucose transporter of the GLUT family, not SLC23A1 (23) , and intracellular dehydroascorbate is immediately reduced to ascorbate-the active form of vitamin C (40) (41) (42) . Because dehydroascorbate is a minor component of some dietary supplements, the proposed gene-specific personalized nutritional therapy would boost intracellular vitamin C concentrations and be considered safe. Confirmation of our findings in independent association studies is warranted before the implementation of any nutritional intervention.
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